Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...
Le Lézard35 分钟
Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results
Net revenue in Q2 FY2025 decreased 9% compared to the second quarter ended September 30, 2023 ("Q2 FY2024"). Excluding net revenue from businesses divested during the prior fiscal year, net revenue ...